my understanding is that RP11 is quite rare and all the numbers quoted are the current numbers of patients that will be able to pay for the drug. So at a billion in sales, approx 4000 patients and they will pay therefore about 250k per annum each. so in reality, each person who dies will get replaced so on an average at 80 yrs life exp. then RP11 is about 50 patients per year in EU US AU and other such economies. So, much rarer.
this second drug will be so much more “company making” and i guess it is actually a matter of whether it makes our company or another company is to join us for the fast tracking of said potential revenue stream.
PYC Price at posting:
17.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)